(Q38208226)

31 August 2017

title

Immunomodulation and AD--down but not out. (English)

1 reference

31 August 2017

E M Knight

1

1 reference

31 August 2017

S Gandy

series ordinal

2

1 reference

31 August 2017

publication date

30 April 2014

1 reference

Journal of Clinical Immunology

31 August 2017

published in

1 reference

31 August 2017

volume

34 Suppl 1

1 reference

31 August 2017

page(s)

S70-3

1 reference

The projected effect of risk factor reduction on Alzheimer's disease prevalence

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Natural human antibodies to amyloid beta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Intravenous immunoglobulin and Alzheimer's disease: what now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0039-Y

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

21 January 2018

1 reference

12 December 2020

2013 Alzheimer's disease facts and figures

1 reference

12 December 2020

Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

1 reference

12 December 2020

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model

1 reference

12 December 2020

Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations

1 reference

12 December 2020

10.1007/S10875-014-0039-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1030390602

0 references

1 reference